Artificial intelligence in precision oncology: The way forward
How to cite this article: Rebolledo-Mendez JD, Vaishnav R. Artificial intelligence in precision oncology: The way forward. Int J Mol Immuno Oncol 2022;3:77-81.
Here, we discuss the positive impact of artificial intelligence (AI) in oncology as an enabler – for physicians, patients, and researchers. AI is here to stay and needs to be better understood by the clinical practitioner and researcher to make informed decisions about cancer diagnoses, treatment, prediction, and long-term care. One immediate impact of data-driven practice will be on cancer stratification based on data that include molecular and imaging markers. Future studies must strengthen the ability to predict causative factors to allow clinicians and patients to take control with the ultimate hope of avoiding preventable cancers.
Artificial intelligence in precision oncology
Artificial Intelligence (AI) and its role in precision oncology
In today’s world, AI has become an inseparable part of our present and future. Due to the advances in computational power and the enormous amounts of digitalization, there is an ever-increasing wealth of data. AI uses the power of algorithms (computer programs) to make inferences by finding features from large amounts of data. Ultimately, the programming of the algorithm is in the hands of the scientists and clinicians who set up the underlying instructions that help the computer make decisions, such as classification. Hence, the algorithms are often based on information and understanding that we, humans, already have (supervised methods) so that predictions can be made using this knowledge. On the other hand, unsupervised methods from machine learning (ML) are where the algorithm manages to learn, analyze, and make inferences from data without human involvement. Thus, in case of a vast field such as precision oncology, there is great value in an open-ended approach such as ML, especially unsupervised algorithms. It would allow the practitioner to “see” information that may not have been evident to them directly. In addition, ML being independent in learning improves as more data become available.
Deep learning (DL) is a type of ML that involves the use of artificial neural networks, which means that it tries to see data the way a human brain sees and processes it by finding features that are mathematically correlated and/or clustered. This approach is very popular in cancer research.
When it comes to precision medicine, oncology remains leaps ahead of many other fields and is always at the forefront in terms of integration of new technology. In addition, with over two decades of data in the post-genomic era, along with the recent additional breadth of information added due to electronic medical records and imaging, there is great potential for utilizing the knowledge for individualized solutions to cancer.
AI has shown an exponential evolution in the recent years. There is an ever-growing list of algorithms for applying learning and brain-based capabilities in cancer research, as summarized in [Table 1] and described in RebolledoMendez, Kulkarni et al., Singh with the abundance of data that can be put together. Historically, very advanced statistical models that were employed in the 1990s gave the push ahead to linear and logistic regression platforms for diagnosis, molecular marker studies, “image-omics,” and “radio-genomics.” The majority of ML algorithms in the 2000s assessed cancer progression, classification of cancers as benign or malignant, cancer stratification by image visualization, correlative markers for early detection, screening, and progression.
Over the decades, combined efforts of teams of computer scientists, physicians, and genomic experts have driven the improved success of AI-driven genomic medicine.
More recent developments include generative adversarial networks – which are basically a form of unsupervised AI, in which new data are generated that mimic real data by trying to beat itself in an objective function. For example, in the case of images, an entirely new image can be created that does not actually exist but is indistinguishable from a real image with as much as 99% accuracy. Quantum machine learning, a more powerful form of ML that uses quantum computers, has recently been able to diagnose and classify non-small-cell lung cancer, deriving its learning from genome-wide human cancer data.
WHY SHOULD THE CLINICAL ONCOLOGIST LEARN ABOUT AI?
Truly, if data are the new oil, the clinician scientist will need to play a key role in helping to “refine” that data and make sure that there is enough quantity of it for meaningful work to be done. Further, any technology has immense potential for good as well as harm. If the clinician is not fully aware of the methodology and the caveats, errors can be made in both diagnosis and treatment.
In 2019, Korfiatis and Ericson reported a simultaneous prediction of four key molecular markers of glioma using DL. DL is advantageous over conventional ML as it allows the researcher to discover new features – so novel molecular markers can be discovered without knowing anything about them. For a clinician, being able to evaluate such studies and use the markers in clinical practice will be an essential skill. Image-omics is rapidly being considered a valuable tool for improving patient stratification, and with improved datasets available for more and more cancer types, it will soon become routine.
CORRELATION VERSUS CAUSATION
A large number of studies in AI are predominantly focused on classification (stratification) or prediction (correlation) [Table 2]. However, causality is not a part of these models. Correlation does not imply causation – it may merely be due to some other cause or a selection bias. The difficulties that oncology poses in trying to determine causality are that cancer data itself are highly complex. There are multiple cross-connecting pathways and various types of data are often sampled in different ways. Further, no two cancers are the same due to inter- and intra-sample heterogeneity. There is a need to move beyond pattern recognition and predictive modeling and refine our approach to look at causality. Reinforcement learning (RL) involves learning the underlying “reward functions” – meaning, what is it that makes a cancer clone survive and evolve into a cancerous state? Mutations accumulate over time and ultimately are a few that drive the survival of the cancer clone. RL can reconstruct the phylogenetic tree of a cancer clone by reverse engineering multi-omic tumor data: Something that decades ago would have taken years of rigorous research is being done within a few months using causal algorithms. The level of sophistication needed in preparing algorithms uniquely suited to precision medicine is exemplified by MethSig that uses hypermethylation across the genome and between samples to predict drivers versus passengers. Identifying clonal signatures and knowing which target to treat are the crux of molecular oncology and where the future of predictive care lies.[48,49]
|Gene selection for cancer classification||Cancer prognosis|
|Survival prediction in lung cancer|
|Malignant and benign clustered microcalcifications||Lung cancer|
|Expressions of very few genes||Leukemia|
|Glioblastoma multiforme cancer using MRI|
Besides molecular markers for prediction, there are countless opportunities for AI application in precision care, particularly with immunotherapies. Knowing which patients will benefit from immunotherapy (and who will not) would prevent unnecessary exposure to harmful side effects and undue financial burden. The various approaches being explored in immuno-oncology include combining complex datasets of tumor biomarkers including immune signatures and 3D tissue imaging to discover new markers. Further, immune escape, drug resistance, and side effects all need to be factored into the models and would require concerted efforts of clinicians and data scientists.
FUTURE OF AI IN PRECISION ONCOLOGY
“Data are the new oil. It’s valuable, but if unrefined it cannot be used.” – Clive Humby, Mathemetician, 2006.
The future is already here – and we are already on the verge of seeing major paradigm shifts in the way we practice clinical medicine. We anticipate more user-friendly digital interfaces in the near future which would allow users (professionals, patients, or even students and citizen scientists) to actively participate in the ongoing curation, mining, and interpretation of cancer data and research literature.
In summary, AI is an enabler – for physicians, patients, and researchers. We will continue to see the impact on cancer stratification, and quantitative imaging will become routine. Further, if we can educate ourselves, the oncology community, about the difference between classification and causative factors, we can start to tackle the bigger problem of avoiding preventable cancers, which is the ultimate goal of the decades-long efforts of molecular and computational medicine. Working together in teams, rather than silos, and developing customized approaches to solving the puzzles unique to precision oncology is the way forward.
There is a growth in development of AI algorithms that can be used to make correlations among data used in oncology. Studies of both stratification and classification are widening. Furthermore, any type of data can be used for getting more precision in oncology via the usage of AI. There is a clear trend that the future will see a continual improvement of AI for better precision oncology.
These references were collected by JRM and RAV; the manuscript was conceptualized and written by JRM and RAV.
Declaration of patient consent
Patient’s consent not required as there are no patients in this study.
Financial support and sponsorship
Conflicts of interest
Dr. Radhika Vaishnav is the Executive Editor of the journal.
- 2005 International Conference on Neural Networks and Brain. Vol 1. 2005. p. :187-90.An Application of Machine Learning in the Criterion Updating of Diagnosis Cancer In:
- [Google Scholar]
- 2005 International Conference on Machine Learning and Cybernetics. Vol 7. 2005. p. :4365-9.Weighted Support Vector Machine for Classification with Uneven Training Class Sizes In:
- [Google Scholar]
- 1997 IEEE Ultrasonics Symposium Proceedings. Vol 2. An International Symposium (Cat. No.97CH36118) 1997. p. :1201-4.Comparison of Different Neuro-Fuzzy Classification Systems for the Detection of Prostate Cancer in Ultrasonic Images In:
- [Google Scholar]
- Cancer Res. 1997;57:4196-9.Pretreatment prediction of the chemotherapeutic response of human glioma cell cultures using nuclear magnetic resonance spectroscopy and artificial neural networks.
- [Google Scholar]
- Proceedings of Canadian Conference on Electrical and Computer Engineering. Vol 1. 1993. p. :337-40.Using the Hopfield Neural Network as a Classifier by Storing Class Representatives In:
- [Google Scholar]
- arXiv. 2018;2018:5719.Lung cancer screening using adaptive memory-augmented recurrent networks.
- [Google Scholar]
- Digital Mammographic Tumor Classification Using Transfer Learning from Deep Convolutional Neural Networks. Available from: https://www.spiedigitallibrary.org/journals/journal-of-medical-imaging/volume-3/issue-3/034501/digital-mammographic-tumor-classification-using-transfer-learning-from-deep-convolutional/10.1117/1.JMI.3.3.034501.full
- [CrossRef] [PubMed] [Google Scholar]